The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.
October 29th 2024
The FDA has expanded the approval of methotrexate to include use in pediatric patients with acute lymphoblastic leukemia.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Eribulin Shows Promise in Pediatric Sarcomas
Eribulin has demonstrated a high level of antitumor activity that was equivalent or superior to vincristine across several sarcoma xenograft models, including at low dose levels, suggesting the drug may effectively treat pediatric patients with sarcoma.
Providing Oncology Services in Impoverished Countries
April 15th 2012Many of us training in the United States have encountered patients and their families from resource-limited regions of the world-families who have uprooted themselves for the chance to save the lives of their children diagnosed with cancer.
Modified Herpes Virus to Be Tested in Sarcoma Patients
The FDA has awarded a $600,000 grant for a phase I clinical trial of a genetically reprogrammed herpes simplex virus in young cancer patients with relapsed non-central nervous system (CNS) solid tumors such as sarcomas and neuroblastomas.